Arcus Biosciences Valuation
| RCUS Stock | USD 9.07 0.02 0.22% |
At this time, the firm appears to be fairly valued. Arcus Biosciences shows a prevailing Real Value of $9.05 per share. The current price of the firm is $9.07. Our model approximates the value of Arcus Biosciences from analyzing the firm fundamentals such as return on equity of -0.6, and Profit Margin of (1.10) % as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Arcus Biosciences' price fluctuation is somewhat reliable at this time. Calculation of the real value of Arcus Biosciences is based on 3 months time horizon. Increasing Arcus Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Arcus stock is determined by what a typical buyer is willing to pay for full or partial control of Arcus Biosciences. Since Arcus Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Arcus Stock. However, Arcus Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.07 | Real 9.05 | Hype 9.07 | Naive 9.28 |
The intrinsic value of Arcus Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Arcus Biosciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Arcus Biosciences helps investors to forecast how Arcus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Arcus Biosciences more accurately as focusing exclusively on Arcus Biosciences' fundamentals will not take into account other important factors: Arcus Biosciences Total Value Analysis
Arcus Biosciences is at this time anticipated to have valuation of 33.51 M with market capitalization of 962.09 M, debt of 48 M, and cash on hands of 1.05 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Arcus Biosciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
33.51 M | 962.09 M | 48 M | 1.05 B |
Arcus Biosciences Investor Information
About 83.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.96. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Arcus Biosciences recorded a loss per share of 3.14. The entity had not issued any dividends in recent years. Based on the key indicators related to Arcus Biosciences' liquidity, profitability, solvency, and operating efficiency, Arcus Biosciences is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Arcus Biosciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Arcus Biosciences has an asset utilization ratio of 22.43 percent. This implies that the Company is making $0.22 for each dollar of assets. An increasing asset utilization means that Arcus Biosciences is more efficient with each dollar of assets it utilizes for everyday operations.Arcus Biosciences Ownership Allocation
Arcus Biosciences holds a total of 105.84 Million outstanding shares. The majority of Arcus Biosciences outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Arcus Biosciences to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Arcus Biosciences. Please pay attention to any change in the institutional holdings of Arcus Biosciences as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Arcus Biosciences Profitability Analysis
The company reported the previous year's revenue of 258 M. Net Loss for the year was (283 M) with loss before overhead, payroll, taxes, and interest of (190 M).About Arcus Biosciences Valuation
The stock valuation mechanism determines Arcus Biosciences' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Arcus Biosciences based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Arcus Biosciences. We calculate exposure to Arcus Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Arcus Biosciences's related companies.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company was incorporated in 2015 and is headquartered in Hayward, California. Arcus Biosciences operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 366 people.
Arcus Biosciences Growth Indicators
Investing in growth stocks can be very risky. If the company such as Arcus Biosciences does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 90.1 M |
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.